We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Still tied up

8 Nov 2005 By Robert Cyran

The Swiss biotech giant s pipeline is poor, its biggest drug s sales have probably peaked, and the group just paid over $700m in fines. So big pharma is unlikely to kick the door in. Serono’s best bet is a partnership with a smaller group which will be hard to arrange.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)